Stool DNA testing climbed sharply after the pandemic began while colonoscopy and fecal immunochemical test use fell, a study of nearly 25 million privately insured Blue Cross Blue Shield beneficiaries found.
The study was published in JAMA Network Open and was led by researchers from New Haven, Conn.-based Yale University and the University of California Los Angeles. They analyzed 24,973,642 commercially insured beneficiaries ages 50-75 from 2017 to 2024. About half were women, and nearly one-third received at least one colorectal cancer screening test during the study period.
Keep Reading
Add A Comment